染料木黄酮植物性雌性激素治疗骨质疏松研究进展

摘要/Abstract

摘要： 本综述通过检索Google Scholar以及Science Direct查阅大量近10年的相关文献,对染料木黄酮抗骨质疏松机制、抗骨质疏松药效、药代动力学以及安全性多角度综述分析。结果表明染料木黄酮具有类似雌性激素作用,与雌性激素受体α的结合力大于雌性激素受体β的结合力,且发挥抗骨质疏松作用的主要作用受体是雌性激素受体α,在抗骨质疏松研究中无论是体内还是体外都具有较强的药理作用;其药理活性作用机制包括抑制骨髓巨噬细胞向破骨细胞转化的能力,抑制破骨细胞的增殖生长能力,诱导破骨细胞的凋亡,同时促进成骨细胞的增殖生长能力。骨质疏松的治疗效果确切,而毒副作用则明显的低于双磷酸盐和特立帕肽。植物雌性激素染料木黄酮可能在未来骨质疏松治疗过程中具有成为一线治疗药物的潜质。

关键词: 染料木黄酮, 植物性雌性激素, 抗骨质疏松

Abstract: Based on the correlative materials of recent 10 year searched from the data base of Google Scholar and Science Direct,the mechanism of anti-osteoporosis, the pharmacological activity of anti-osteoporosis, the pharmacokinetics, drug safety of genistein had been briefly summarized overlaying multiple perspectives. The binding force of genistein to the estrogen receptor α is greater than that to the estrogen receptor β and the primary receptor of its pharmacological activity of anti-osteoporosis is estrogen receptor α.Whatever in vitro or in vivo, all the reports below indicate the anti-osteoporosis ability of genistein is surprising. The pharmacology activity of genistein includes inhibited the ability of bone marrow macrophage translated into to osteoclast , inhibited the proliferation ability of osteoclast , induced the apoptosis of osteoclasts, and promoted the proliferation ability of osteoblast.Therapeutic efficacy of anti-osteoporosis is definite, but the toxic and side effect is less than diphosphonate and teriparatide. Geniste has the potential of becoming the clinical first-line drug in treatment of osteoporosis in the future.

Key words: Genistein, Plant estrogen, Anti-osteoporosis

中图分类号:

R587

林忠, 孙渊, 杜有功, 杨建苗, 林建群. 染料木黄酮植物性雌性激素治疗骨质疏松研究进展[J]. 中国临床药理学与治疗学, 2014, 19(1): 105-111.

LIN Zhong, SUN Yuan, DU You-gong, YANG Jian-miao, LIN Jian-qun. The research progress of plant estrogen genistein in osteoporosis treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 105-111.

参考文献

[1] Devogelaer JP. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach[J]. Rheum Dis Clin North Am, 2006,32(4):733-757.
[2] Sambrook PN. Anabolic therapy in glucocorticoid-induced osteoporosis[J]. N Engl J Med,2007, 357(20): 2084-2086.
[3] Wu Q, Bencaz AF, Hentz JG, et al. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies[J]. Osteoporos Int,2012,23(1):365-375.
[4] Dennison E, Cole Z, Cooper C, et al. Diagnosis and epidemiology of osteoporosis[J]. Curr Opin Rheumatol,2005,17(4):456-461.
[5] Brand ML. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases[J]. Osteoporosis International,1996, 6 (Supple1) :317.
[6] Arjmandi BH, Alekei L, Hollis B, et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis[J]. J Nutr, 1996,126(1): 161-167.
[7] Gao YH, Yamaguchi M. Inhibitory effect of genistein on osteoclast-like cell formation inmouse marrow cultures[J]. Biochem Pharmacol, 1999,58(5): 767-772.
[8] Sugimoto E, Yamaguchi M. Anabolic effect of genistein in osteoblastic MC3T3-E1 cells[J]. Int J Mol Med,2000, 5(5): 515-520.
[9] Yamaguchi M, Gao YH. Anabolic effect of daidzein on cortical bone in tissue culture: Comparison with genistein effect[J].Molecular and Cellular Biochemistry, 1999,194(1): 93-98.
[10] Li XL, Wang NL, Wong MS, et al. Four new isoflavonoids from the stem bark of Erythrina variegate[J]. Chem Pharm Bull, 2006,54(4):570-573.
[11] Yan Z, Xiao LL, Xin SY, et al. Osteogenic Activities of genistein derivatives were influenced by the presence of prenyl group at ring A[J]. Arch Pharm Res, 2008,31(12):1534-1539.
[12] Ruchun D, Yulin M, Zhifeng S, et al. Effects of genistein on vertebral trabecular bone microstructure, bone mineral density, microcracks, osteocyte density, and bone strength in ovariectomized rats[J]. J Bone Miner Metab,2008,26(4):342-349.
[13] Zhang Y, Li Q, Wan HY, et al. Genistein and a soy extract differentially affect three-dimensional bone parameters and bone-specific gene expression in ovariectomized mice[J].J Nutr,2009, 139(12):2230-2236.
[14] Ferrettia M, Bertonib L, Cavania F.Structural and histomorphometric evaluations of ferutinin effects on the uterus of ovariectomized rats during osteoporosis treatment[J].Life Sciences,2012,90 (3):161-168.
[15] Catherine A, Schnell JD, Kubas KL, et al. Effects of soy isoflavone consumption on bone structure and milk mineral concentration in a rat model of lactation-associated bone loss[J]. Eur J Nutr,2009,48(2):84-91.
[16] Hyekyung H, Young LH, Jehyun L, et al. Formononetin prevents ovariectomy-induced bone loss in rats[J]. Arch Pharm Res, 2010,33, (4) :625-632.
[17] Rayalam S, Dellafera MA, Clifton A, et al. Synergism between resveratrol and other phytochemicals:Implications for obesity and osteoporosis[J]. Molecular nutrition and food, 2011,55 (8):1177-1185.
[18] Bitto A, Burnett BP, Polito F. Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate[J]. Bri J Pharmacol, 2009, 156(8): 1287-1295.
[19] Dai R, Ma Y, Sheng Z,et al. Effects of genistein on vertebral trabecular bone microstructure, bone mineral density, microcracks, osteocyte density, and bone strength in ovariectomized rats[J]. J Bone Miner Metab, 2008, 26(4): 342-349.
[20] Choi SY, Ha TY, Ahn JY, et al. Estrogenic activities of isoflavones and flavones and their structure-activity relationships[J]. Planta Med, 2008, 74(1): 25-32.
[21] Liu Y, Hu M. Absorption and metabolism of flavonoids in the Caco-2 cell culture model and a perused rat intestinal model[J]. Drug Metab Dispos, 2002, 30(4): 370-377.
[22] Chen J, Lin H, Hu M, Metabolism of flavonoids via enteric recycling: role of intestinal disposition[J] J. Pharmacol Exp Ther,2003, 304(3):1228-1235.
[23] Uwe U, Juergen M, Thomas F, et al. Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein in healthy volunteers[J]. Advances in Therapy, 2005, 22 (1): 65-78.
[24] Marini H, Bitto A, Altavilla D, et al. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study[J].J Clin Endocrinol Metab,2008, 93(12):4787-4796.
[25] Brandi ML. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases [J]. Calcif Tissue Int,1997,61 (Suppl 1): 5-8.
[26] Paech K, Webb P, Kuiper GG. Differential ligand activation of estrogen receptors ER αand ERβ at AP-1 sites [J]. Science , 1997, 277(3):1508 - 1510.
[27] Waters KM, Rickard DJ, Riggs BL, et al. Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform[J]. J Cell Biochem, 2001, 83(3): 448 -462.
[28] Rickard DG, Monroe TJ, Ruesink S. Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors α and β[J]. J Cell Biochem, 2003, 89(3): 633-646.
[29] Hertrampfa MJ, Grucaa J, Seibela U. The bone-protective effect of the phytoestrogen genistein is mediated via ERα-dependent mechanisms and strongly enhanced by physical activity[J]. Bone, 2007,40(6):1529-1535.
[30] Satoshi U, Masayoshi, Yamaguchi PD. Genistein and zinc synergistically stimulate apoptotic cell death and suppress RANKL signaling-related gene expression in osteoclastic cells[J]. J Cell Biochem, 2007,101(3):529-542.
[31] Matsukawa Y, Marui N, Sakai T, et al. Genistein arrests cell cycle progression at G2M[J]. Cancer Research, 1993, 53(4):1328-1331.
[32] Gao YH, Yamaguchi M. Suppressive effect of genistein on rat bone osteoclasts: apoptosis is induced through Ca²⁺ signaling[J]. Biol Pharm. Bull, 1999, 22(8):805-809.
[33] Yamaguchi M, Gao YH. Inhibitory effect of genistein on bone resorption in tissue culture[J].Biochem Pharmacol,1998,55(1): 71-76.
[34] Rickard, Monroe, Ruesink. Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta[J]. J Cell Biochem,2003,89(3): 633-646.
[35] Yan Z, Qi L, Hoi YW. Genistein and a Soy Extract Differentially Affect three-dimensional bone parameters and bone-specific gene expression in ovariectomized mice [J]. J Nutr, 2009,139(12): 2230-2236.
[36] Zhang Y, Li Q, Wan HY. Study of the mechanisms by which Sambucus williamsii HANCE extract exert protective effects against ovariectomy-induced osteoporosis in vivo[J]. Osteoporos Int, 2010, 22 (2): 703-709.
[37] Van STP. The pathogenesis, epidemiology and management of glucocorticoid-inducedosteoporosis [J]. Calcif Tissue Int,2006,79(3): 129-137.
[38] Civitelli R, Ziambaras K. Epidemiology of glucocorticoid-induced osteoporosis [J]. J Endocrinol Invest, 2008, 31 (7 Suppl): 2-6.
[39] Prinsloo PJJ, Hosking DJ. Alendronate sodium in the management of osteoporosis[J]. J Therap Clin Risk Manag, 2006, 2(3): 235-249.
[40] Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, andmuscle pain[J]. Arch Int Med,2005,165(3): 346-347.